|
|
| Research article summary (published 29 Sep 2009): |
Dendritic cell therapy of high-grade gliomas.
Full Abstract
The prognosis of patients with malignant glioma is poor in spite of multimodal treatment approaches consisting of neurosurgery, radiochemotherapy and maintenance chemotherapy. Among innovative treatment strategies like targeted therapy, antiangiogenesis and gene therapy approaches, immunotherapy emerges as a meaningful and feasible treatment approach for inducing long-term survival in at least a subpopulation of these patients. Setting up immunotherapy for an inherent immunosuppressive tumor located in an immune-privileged environment requires integration of a lot of scientific input and knowledge of both tumor immunology and neuro-oncology. The field of immunotherapy is moving into the direction of active specific immunotherapy using autologous dendritic cells (DCs) as vehicle for immunization. In the translational research program of the authors, the whole cascade from bench to bed to bench of active specific immunotherapy for malignant glioma is covered, including proof of principle experiments to demonstrate immunogenicity of patient-derived mature DCs loaded with autologous tumor lysate, preclinical in vivo experiments in a murine orthotopic glioma model, early phase I/II clinical trials for relapsing patients, a phase II trial for patients with newly diagnosed glioblastoma (GBM) for whom immunotherapy is integrated in the current multimodal treatment, and laboratory analyses of patient samples. The strategies and results of this program are discussed in the light of the internationally available scientific literature in this fast-moving field of basic science and translational clinical research.
Author information
Author/s: Van Gool, Stefaan (S); Maes, Wim (W); Ardon, Hilko (H); Verschuere, Tina (T); Van Cauter, Sofie (S); De Vleeschouwer, Steven (S);
Affiliation: Laboratory of Experimental Immunology, and Department of Child & Woman, Catholic University of Leuven, Leuven, Belgium. stefaan.vangool(-atsign-)uz.kuleuven.be
Journal and publication information
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
Journal: Brain pathology (Zurich, Switzerland) (Brain Pathol), published in Switzerland. (Language: eng)
Reference: 2009-Oct; vol 19 (issue 4) : pp 694-712
Dates: Created 2009/09/11; Completed 2009/11/04;
PMID: 19744041, status: MEDLINE (last retrieval date: 11/4/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Dendritic cell vaccines and immunity in glioma patients.
30 Aug 2005 - Peptide-based immunotherapeutic approaches to glioma: a review.
29 Apr 2007 - Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
24 Apr 2008 - T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches.
30 Aug 2005 - Novel immunotherapeutic approaches to glioma.
30 Jan 2006 - Dendritic cell-based immunotherapy for malignant gliomas.
29 Jun 2005 - [Immunotherapy for glioma]
30 May 2008 - Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
29 Apr 2008 - Extending survival in gliomas: surgical resection or immunotherapy?
30 Jan 2004 - Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model.
29 Mar 2006
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.